Technical Analysis on Sequenom Inc. and Biogen Idec Inc. -

Technical Analysis on Sequenom Inc. and Biogen Idec Inc. - Biotech
Momentum Slowing 
NEW YORK, NY -- (Marketwire) -- 11/07/12 --   Biotechnology companies
are performing well as a whole at the moment but a variety of factors
threaten to undo the industry's momentum. Technological turnover,
competitive pressure and the need to get new products to market are
all making it difficult to widen margins. Players in the Biotech
space like Sequenom Inc. and Biogen Idec Inc. are contending
admirably with these headwinds at the moment though. StBulls.com has
initiated technical analysis on Sequenom Inc. (NASDAQ: SQNM) and
Biogen Idec Inc. (NASDAQ: BIIB) which serves the Biotechnology
industry. These reports are free upon registration at  
http://www.stbulls.com/  
www.StBulls.com enthuses to bring the best from the internet under
one roof, providing you with a one click opportunity to view what the
market and financial researchers globally have to say about any
particular bellwether stocks in any given financial environment. We
work with a number of financial professionals and a dedicated team of
researchers that use their acute knowledge to help you manage your
understanding of the market. To be part of this community please sign
up at
 http://www.stbulls.com/  
The trouble created by technological turnover is most evident in the
diagnostic side of the industry. Not only are new products coming out
at a faster rate but they are also able to complete tasks at a
fraction of the cost of the previous generation. Read our technical
analysis on Sequenom Inc. by clicking on  
http://www.stbulls.com/SequenomInc07112012.pdf  
Competitive threats and the need to get new drugs to market are more
of a factor in the drug side of the industry. Acquisition activity
remains strong as many companies look to quickly expand their
portfolio of offerings and stave off generic competition. Investors
may want to take a closer look at biotech firms successfully getting
drugs through trials for the best long-term growth prospects. Read
our technical analysis on Biogen Idec at 
http://www.stbulls.com/BiogenIdecInc07112012.pdf  
About Street Bulls
 STREET BULLS is committed to provide the investor
community with sharp and timely trading and investing advice. Our aim
is to help our readers achieve above-average returns from the markets
and create wealth for themselves. Our newsletters and trading advice
will provide investors with the information they need for success in
today's volatile markets. 
To view our disclaimer, use this link  
http://www.stbulls.com/disclaimer.html. 
Contact Person: 
Martin Peters
Marketing Consultant
info@stbulls.com 
 
 
Press spacebar to pause and continue. Press esc to stop.